Diagenode

Banner showing blood and plasma

DNA methylation:
overcoming
early detection
challenges in cancer

Learn how

We applied our 20 years of epigenomic expertise to assist Universal Diagnostics (UDx) in developing a unique and customized early-detection workflow for colorectal cancer (CRC). This approach combines liquid biopsies with DNA methylation technologies for biomarker discovery and subsequent biomarker validation.

Liquid biopsy illustration

Capturing biomarkers in real-time with liquid biopsy

Using cell-free DNA (cfDNA) isolated from plasma, biomarkers were monitored in real-time in the risk population.

We helped identify the best sample prep options in terms of quantity, quality, reproducibility and high-throughput for regular screening of cfDNA from plasma.

classification illustration

DNA methylation for cancer classification

Genome-wide methylation profiles from healthy and cancer patients were created to identify potential biomarkers.

Using our WGBS/EM-seq service, UDx identified DNA methylation patterns associated with each CRC grade.

biomarkers passing through a funnel

Validating biomarkers for performance

Once a pool of potential biomarkers was available, we identified the best performers.

Thanks to our Targeted Methyl-seq service, UDx narrowed down the candidates, and we validated a set of biomarkers that performs reliably with an NGS assay.



“With the help of Hologic Diagenode’s experts, we are developing blood tests that detect cancer in its earliest stages.”

Picture of Kristi Kruusmaa

Kristi Kruusmaa
Chief Scientific Officer
Universal Diagnostics



Events

 See all events

 


       Site map   |   Contact us   |   Conditions of sales   |   Conditions of purchase   |   Privacy policy